Catalyst Brief

← Calendar

Readoutin 104d

Bristol-Myers Squibb — Nivolumab

Phase 3 primary completion: A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer.

Date
Mar 2027
Type
Readout
Indication
Renal Cell Carcinoma

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Bristol-Myers Squibb

  1. Nov2026